00000nam 2200000zi 4500 9.934200 CaOODSP 20240411084314 m o d f cr mn||||||||| 240220e202403 onca ob f000 0 eng d 9780660703923 CaOODSP eng rda CaOODSP n-cn--- HP5-239/3-2024E-PDF Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines : economic evidence supplementary appendix. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, March 2024. ©2024 1 online resource (56 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. Issued also in French under title: Recommandations pour les programmes de santé publique sur l'utilisation des vaccins contre le pneumocoque chez les enfants, y compris l'utilisation des vaccins conjugués 15-valent et 20-valent : annexe complémentaire sur les données probantes économiques. At head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). "Pub.: 230769." Includes bibliographical references (pages 50-56). Vaccination Economic aspects Canada. Vaccination of children Canada. Pneumococcal vaccine Canada. Streptococcus pneumoniae Vaccination Canada. Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. Recommandations pour les programmes de santé publique sur l'utilisation des vaccins contre le pneumocoque chez les enfants, y compris l'utilisation des vaccins conjugués 15-valent et 20-valent : (CaOODSP)9.934201 PDF 1.69 MB https://publications.gc.ca/collections/collection_2024/aspc-phac/HP5-239-3-2024-eng.pdf